Biljana Rizoska

2PUBLICATIONS
0CO-AUTHORS
Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (2)

|May 11, 2018
Nonclinical and clinical pharmacological characterization of the potent and selective cathepsin K inhibitor MIV-711.

Erik Lindström, Biljana Rizoska, Ian Henderson

|Mar 11, 2018
The selective cathepsin K inhibitor MIV-711 attenuates joint pathology in experimental animal models of osteoarthritis.

Erik Lindström, Biljana Rizoska, Karin Tunblad

Pageof 1

Frequent Collaborators